Drug interactions in English: source-based medicine pair records

These records are for information and research. Do not start, stop or change medicines based on a web page. Product formulations, licensed uses and advice can differ by country.

• Abacavir and Lamivudine: interaction and safety

  This record applies when lamivudine is given with a sorbitol-containing abacavir oral solution, such as ZIAGEN oral solution. Sorbitol can reduce lamivudine exposure, and the…

• Abacavir and Maraviroc: interaction and safety

  The maraviroc label places Abacavir among its noninteracting antiretroviral co-medications, so a CYP3A-based adjustment is not triggered by this medicine alone. This does not…

• Abacavir and Methadone: interaction and safety

  Abacavir is specifically listed among antiretrovirals associated with increased methadone clearance or lower methadone levels. Reduced opioid effect or withdrawal can follow,…

• Abacavir and Riociguat: interaction and safety

  Increased riociguat exposure was reported with fixed-dose abacavir/dolutegravir/lamivudine. This may increase riociguat adverse effects, so the prescriber should review the co…

• Abemaciclib and Anastrozole: interaction and safety

  Abemaciclib and Anastrozole may be used together as part of an appropriate breast-cancer regimen selected by the oncology team. The absence of a clinically relevant pharmacoki…

• Abemaciclib and Apalutamide: interaction and safety

  Abemaciclib with Apalutamide can reduce the effectiveness of the affected anticancer treatment. The product information recommends avoiding strong CYP3A inducers where possibl…

• Abemaciclib and Diflucan 150 mg (Fluconazole): interaction and safety

  With Abemaciclib and Diflucan 150 mg (Fluconazole), monitor abemaciclib-related adverse effects, including diarrhoea and blood-count abnormalities. The EMA product information…

• Abemaciclib and Enzalutamide: interaction and safety

  Abemaciclib with Enzalutamide can reduce the effectiveness of the affected anticancer treatment. The product information recommends avoiding strong CYP3A inducers where possib…

• Abemaciclib and Exemestane: interaction and safety

  Abemaciclib and Exemestane may be used together as part of an appropriate breast-cancer regimen selected by the oncology team. The absence of a clinically relevant pharmacokin…

• Abemaciclib and Glucophage (Metformin) (Glucophage 500 mg): interaction and safety

  Abemaciclib with Glucophage (Metformin) is not automatically contraindicated. A clinical study found a small increase in metformin exposure that was not considered clinically…

• Abemaciclib and Imodium (Loperamide) (İmodium 2 mg): interaction and safety

  Abemaciclib with Imodium (Loperamide) is not automatically prohibited because of this interaction record. Loperamide may form part of the clinician’s plan for abemaciclib-asso…

• Abemaciclib and Isavuconazole: interaction and safety

  With Abemaciclib and Isavuconazole, monitor abemaciclib-related adverse effects, including diarrhoea and blood-count abnormalities. The EMA product information does not requir…

• Abemaciclib and Paxlovid (Nirmatrelvir/Ritonavir) (Paxlovid 150 mg/100 mg Film Kaplı Tablet): interaction and safety

  Abemaciclib with Paxlovid (Nirmatrelvir/Ritonavir) can increase exposure to the affected anticancer medicine and raise the risk of serious adverse effects. Strong CYP3A inhibi…

• Abemaciclib and Posaconazole: interaction and safety

  Abemaciclib with Posaconazole can increase exposure to the affected anticancer medicine and raise the risk of serious adverse effects. Strong CYP3A inhibitors should be avoide…

• Abemaciclib and Ribociclib: interaction and safety

  The interaction between Abemaciclib and Ribociclib depends on the ribociclib regimen and on the other anticancer medicine’s product information. The rules for a strong inhibit…

• Abilify (aripiprazole) (Abilify 5 mg) and Buprenorphine: interaction and safety

  Buprenorphine and aripiprazole can have additive depressant effects, increasing sedation and the risk of slow breathing, coma or death. The prescriber should review the combin…

• Abilify (aripiprazole) (Abilify 5 mg) and Cariprazine: interaction and safety

  Abilify (aripiprazole) and Cariprazine: Centrally acting medicines require caution because dizziness and mental or motor impairment may overlap. Drowsiness, dizziness, reduced…

• Abilify (aripiprazole) (Abilify 5 mg) and Doxepin: interaction and safety

  Abilify (aripiprazole) and Doxepin: Other CNS depressants may increase the sedation caused by low-dose doxepin. Drowsiness, dizziness, reduced coordination and falls can be mo…

• Abilify (aripiprazole) (Abilify 5 mg) and Eszopiclone: interaction and safety

  Abilify (aripiprazole) and Eszopiclone: Eszopiclone and other CNS depressants may produce additive sedation. Drowsiness, dizziness, reduced coordination and falls can be more…

• Abilify (aripiprazole) (Abilify 5 mg) and Fentanyl: interaction and safety

  Fentanyl and aripiprazole can have additive depressant effects, increasing sedation and the risk of slow breathing, coma or death. The prescriber should review the combination…

• Abilify (aripiprazole) (Abilify 5 mg) and Flupentixol: interaction and safety

  Abilify (aripiprazole) and Flupentixol: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Concurrent antipsychotic treatment or a plan…

• Abilify (aripiprazole) (Abilify 5 mg) and Glycopyrrolate: interaction and safety

  Abilify (aripiprazole) and Glycopyrrolate: Adding an anticholinergic during antipsychotic treatment can worsen or mask tardive dyskinesia. Anticholinergics may mask or aggrava…

• Abilify (aripiprazole) (Abilify 5 mg) and Methadone: interaction and safety

  The listed product includes aripiprazole; its antipsychotic component can add to methadone effects, causing marked sedation, low blood pressure and potentially fatal breathing…

• Abilify (aripiprazole) (Abilify 5 mg) and Morphine: interaction and safety

  The listed product includes aripiprazole; its antipsychotic component can add to morphine effects, causing marked sedation, low blood pressure and potentially fatal breathing…

• Abilify (aripiprazole) (Abilify 5 mg) and Nortriptyline: interaction and safety

  Abilify (aripiprazole) and Nortriptyline: Nortriptyline may increase the sedative effects of other CNS depressants. Tricyclic antidepressant and neuroleptic co-treatment carri…

• Abilify (aripiprazole) (Abilify 5 mg) and Oxycodone: interaction and safety

  Oxycodone and aripiprazole can have additive depressant effects, increasing sedation and the risk of slow breathing, coma or death. The prescriber should review the combinatio…

• Abilify (aripiprazole) (Abilify 5 mg) and Pimozide: interaction and safety

  Abilify (aripiprazole) and Pimozide: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Concurrent antipsychotic treatment or a planned…

• Abilify (aripiprazole) (Abilify 5 mg) and Ramelteon: interaction and safety

  Abilify (aripiprazole) and Ramelteon: Other CNS depressants may increase impaired alertness and complex sleep behaviours. Drowsiness, dizziness, reduced coordination and falls…

• Abilify (aripiprazole) (Abilify 5 mg) and Ropinirole: interaction and safety

  Abilify (aripiprazole) and Ropinirole: Dopamine-blocking antipsychotics and metoclopramide can oppose ropinirole's therapeutic effect. A loss of Parkinson treatment benefit or…

• Abilify (aripiprazole) (Abilify 5 mg) and Suvorexant: interaction and safety

  Abilify (aripiprazole) and Suvorexant: Suvorexant and other sedating medicines may have additive CNS depressant effects. Drowsiness, dizziness, reduced coordination and falls…

• Abilify (aripiprazole) (Abilify 5 mg) and Trifluoperazine: interaction and safety

  Abilify (aripiprazole) and Trifluoperazine: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Concurrent antipsychotic treatment or a…

• Abilify (aripiprazole) (Abilify 5 mg) and Zolpidem: interaction and safety

  Abilify (aripiprazole) and Zolpidem: Other centrally acting medicines may increase zolpidem-related sedation and psychomotor impairment. Drowsiness, dizziness, reduced coordin…

• Abilify (aripiprazole) (Abilify 5 mg) and Zonisamide: interaction and safety

  Abilify (aripiprazole) and Zonisamide: Other CNS depressants may increase zonisamide-related drowsiness, cognitive slowing and balance problems. Drowsiness, dizziness, reduced…

• Abilify (aripiprazole) (Abilify 5 mg) and Zuclopenthixol: interaction and safety

  Abilify (aripiprazole) and Zuclopenthixol: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Concurrent antipsychotic treatment or a p…

• Abiraterone and Apalutamide: interaction and safety

  Abiraterone with Apalutamide can reduce abiraterone exposure and potentially reduce cancer-treatment effectiveness. The current US Zytiga prescribing information recommends av…

• Abiraterone and Enzalutamide: interaction and safety

  Abiraterone with Enzalutamide can reduce abiraterone exposure and potentially reduce cancer-treatment effectiveness. The current US Zytiga prescribing information recommends a…

• Abiraterone and Fluphenazine: interaction and safety

  Abiraterone and Fluphenazine: CYP2D6 inhibition may increase antipsychotic exposure. Changes in exposure can affect tolerability or treatment response. The prescriber must che…

• Abiraterone and Pimozide: interaction and safety

  Abiraterone and Pimozide: Abiraterone's CYP2D6 inhibition may increase pimozide exposure. This combination is contraindicated under the cited pimozide product information. It…

• Abiraterone and Rifabutin: interaction and safety

  Abiraterone with Rifabutin can reduce abiraterone exposure and potentially reduce cancer-treatment effectiveness. The current US Zytiga prescribing information recommends avoi…

• Abiraterone and Sotalol: interaction and safety

  Abiraterone and Sotalol: Androgen deprivation and abiraterone-related hypokalaemia can increase cardiac risk with a QT-prolonging partner. Heart disease, a slow pulse and low…

• Abiraterone and Zuclopenthixol: interaction and safety

  Abiraterone and Zuclopenthixol: CYP2D6 inhibition may increase antipsychotic exposure. Changes in exposure can affect tolerability or treatment response. The prescriber must c…

• Abrocitinib and Apalutamide: interaction and safety

  Apalutamide contains an inducer that meets the abrocitinib label’s CYP2C19 interaction criteria. Reduced exposure can weaken treatment response, and coadministration should be…

• Abrocitinib and Aspirin (Aspirin 500 mg): interaction and safety

  Aspirin 500 mg has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day or less. T…

• Abrocitinib and Aspirin (Coraspin 100 mg): interaction and safety

  Coraspin 100 mg has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day or less.…

• Abrocitinib and Aspirin (Dispril 400 mg): interaction and safety

  Dispril 400 mg has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day or less. T…

• Abrocitinib and Aspirin (Ecopirin 100 mg): interaction and safety

  Ecopirin 100 mg has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day or less.…

• Abrocitinib and Baricitinib: interaction and safety

  Baricitinib and abrocitinib are both oral JAK inhibitors. The referenced prescribing information does not recommend combining the JAK inhibitor with another medicine in this c…

• Abrocitinib and Ciclosporin (Sandimmun Neoral 100 mg Yumuşak Jelatin Kapsül): interaction and safety

  Abrocitinib labeling does not recommend combination with other immunosuppressants. Sandimmun Neoral 100 mg Yumuşak Jelatin Kapsül represents systemic immunosuppressive therapy…

• Abrocitinib and Cilostazol (Pletal 100 mg Tablet): interaction and safety

  Pletal 100 mg Tablet has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day or l…

• Abrocitinib and Clopidogrel (Klopidogrel Bilim 75 mg): interaction and safety

  Klopidogrel Bilim 75 mg has antiplatelet activity. The U.S. abrocitinib label contraindicates antiplatelet therapy during the first three months, except aspirin at 81 mg/day o…